Share:
“Grand View Research, Inc. – Market Research And Consulting.”
According to report published by Grand View Research, The rising prevalence of castrate-resistant prostate cancer, growing adoption of novel drugs, along with an unhealthy lifestyle are key factors anticipated to accelerate market growth. The need for faster treatment options and investments in R&D by key players is also fueling the growth rate of the market.
Castrate-resistant Prostate Cancer Market Growth & Trends
The global
castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.
Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events
Share Article
The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, is pleased to announce the publication of a clinical practice guideline for the management of cell therapy adverse events. Immune effector cell therapies include the three U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cell products for treatment of blood-based cancers.
“This is the tenth manuscript published in SITC’s Cancer Immunotherapy Guidelines series, a critically important effort to educate physicians and other health care providers, and improve outcomes for cancer patients receiving FDA-approved immunotherapies, said SITC President Mario Sznol, MD.
National Academy of Inventors names Gordon Freeman a 2020 Fellow miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
IPO Alert: Nanobiotix (NBTX)
PARIS (dpa-AFX) - Paris, France-based Nanobiotix, which is currently listed on the Euronext Paris stock exchange, is scheduled to list its American Depositary Shares (ADSs) on the Nasdaq Global Market under the symbol NBTX today (December 11).
Nanobiotix is a clinical-stage biotechnology company developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy.
The company has offered to sell 5.45 million American Depositary Shares in the United States for a price of $13.50 per ADS and 1.86 million ordinary shares in certain jurisdictions outside of the United States to certain investors. The aggregate gross proceeds are expected to be approximately $98.6 million.